# Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia

> **NCT00265551** · PHASE2 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 300 (—)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** SCA-136 (200 mg)
- **DRUG:** SCA-136 (400 mg)
- **DRUG:** olanzapine (15 mg)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00265551
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** —
- **Final completion:** 2007-01
- **Target enrollment:** 300 (—)
- **Last updated:** 2007-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00265551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00265551, "Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00265551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*